Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501074 | 1.00 | FUCA1 (0.71) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL501072 | 1.00 | FUCA1 (0.71) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL19497342 | 1.00 | FUCA1 (0.71) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL500554 | 1.00 | FUCA1 (0.71) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL500287 | 1.00 | FUCA1 (0.71) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL5745371 | 0.91 | FUCA1 (0.59) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL6962228 | 0.90 | FUCA1 (0.77) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL915827 | 0.90 | FUCA1 (0.77) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL21462952 | 0.87 | FUCA1 (0.68) | FUCA1MAPTGBA1ACHEALDH1A1 | |
| SCHEMBL21462951 | 0.87 | FUCA1 (0.68) | FUCA1MAPTGBA1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-113493628-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-1486500-B1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIA | KYORIN SEIYAKU KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| EP-1288198-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6479668-B1 | Method of producing pyrrolidine derivatives | TORAY INDUSTRIES, INC. (JP) | 2002-11-12 | — | — | US | disclosed |
| US-6130338-A | OXIDATING THE CORRESPONDING 3-PYRROLINE COMPOUND TO GIVE AN EPOXYPYRROLIDINE COMPOUND | TORAY INDUSTRIES, INC. (JP) | 2000-10-10 | — | — | US | disclosed |
| EP-0985664-A2 | Method of producing pyrrolidine derivatives | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| EP-0562042-A4 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0562042-A1 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1993-09-29 | — | — | EP | disclosed |
| US-5137892-A | Bactericides | ABBOTT LABORATORIES (US) | 1992-08-11 | — | — | US | disclosed |
| WO-1992010191-A1 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0443498-A1 | Isoindoline derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | FUCA1 3491/4885MAPT 4843/4885GBA1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.